A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesAre we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis opticaAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyCD19 as an attractive target for antibody-based therapyReceptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical developmentCurrent and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodiesAntibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Antibody therapy of pediatric B-cell lymphomaXmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Novel monoclonal antibodies for therapy of multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Breakthrough therapies in B-cell non-Hodgkin lymphoma.A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay.7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.
P2860
Q21131216-DB267D4C-8978-479B-9FB1-464454C00779Q24597424-AC96CDE0-5A1F-4478-9502-E9EB17591BCDQ26748601-C926B0C5-C6E2-4408-A93A-480ABAA74956Q26775363-2AB940BE-4ED0-4FFE-A5FF-93F7A657D25FQ27011836-5E50517F-AFBE-413A-9C8F-BC7235FE9999Q28084276-A66760A2-7C89-4D51-8D1E-F343A948DFA1Q34440110-80CAEE24-4752-451E-89A9-0DE560CB0B6BQ34598149-3F50A572-BD87-4682-BF68-60A9A88FC1A6Q36539682-FE49F401-FDCF-480C-A442-51A40183595DQ36732959-BDF466E0-EB8C-49F9-853C-4980871CF25CQ36913118-30707F8E-20AC-43E0-AD09-9960B1839FF2Q36975931-49B1DA06-D4AD-48A8-B620-A8AD7D990C42Q37019872-B35A8DD3-A552-4F7F-8AA5-C8AD1C6953E7Q38191996-1F7F6127-C6F3-4FFF-BC30-16AFF4945407Q38364547-61EDFD29-EFED-496F-8143-9B96DB3DAD67Q38445357-A1F4C52B-1294-4402-AE15-D68AB8F08B48Q38543771-ABC0EA68-1FA5-4239-A457-81C61EE84C2CQ38708600-A5EA1C5D-BD53-45DD-AB20-8273495C9260Q38850042-D2501D08-4BE1-4001-B4D4-1308A03F08FCQ39004366-E7E23971-1B9A-4D23-9FCE-558B8B8EF8BBQ39119839-F38D9B7E-FF30-4ED1-AE0A-F2A429618420Q39279968-5737C8B5-B299-471B-881F-FC729D90E463Q41872171-D588F5DD-D362-4FE7-A284-B424663B8685Q42333450-C04F5BC2-B2FC-44B7-B8B6-0B81439D33F1Q44133396-0D2FB08C-C7B2-4EEF-A3B0-293969CB9FBBQ48134110-D058DC07-72AD-434F-9434-1512703DFF97Q49539698-0FCA03EB-D32B-4D82-814F-BE04077738E0Q53264199-A9DB9051-2FE0-4C75-95C2-5A4719C15C01Q53758334-1239C3AD-532F-4205-8676-B3357688B5DD
P2860
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A glycoengineered anti-CD19 an ...... oma growth inhibition in vivo.
@en
A glycoengineered anti-CD19 an ...... oma growth inhibition in vivo.
@nl
type
label
A glycoengineered anti-CD19 an ...... oma growth inhibition in vivo.
@en
A glycoengineered anti-CD19 an ...... oma growth inhibition in vivo.
@nl
prefLabel
A glycoengineered anti-CD19 an ...... oma growth inhibition in vivo.
@en
A glycoengineered anti-CD19 an ...... oma growth inhibition in vivo.
@nl
P2093
P2860
P1476
A glycoengineered anti-CD19 an ...... oma growth inhibition in vivo.
@en
P2093
Anthony J Coyle
Bahija Jallal
Elizabeth Ward
Ellen Kuta
Gary P Sims
Michael A Bowen
Nanette Mittereder
Peter Kiener
Ronald Herbst
P2860
P304
P356
10.1111/J.1365-2141.2011.08857.X
P407
P577
2011-09-09T00:00:00Z